Outcomes among the best in the nation

Choosing where to bring your child for cancer and blood disorders care is a major decision. You need all the information you can get. And you want it in a clear, straightforward form that helps you make the right choice for your family.

That’s why we share our outcomes with you. In medicine, “outcomes” measure the end results of a treatment. By comparing our outcomes with those of other hospitals, locally and nationally, you can see how we rank in terms of keeping patients safe and healthy.

See how Children’s ranks on quality of care measures and learn about our cancer and blood disorders program outcomes.

Finding new ways to improve comfort and care

At Children’s, we focus on research and innovations that make a difference at the bedside. From improving day-to-day quality of life for children and teens to developing new pain management approaches and adopting top-of-the-line technologies, our research is completely kid-and family-focused.  Learn more about our Supportive Care Research.

Children’s is engaged in many types of cancer and blood disorders research, including investigator-initiated studies (led by a Children’s clinician), as well as externally sponsored multicenter trials, observational studies, and registries.

Research studies are ongoing in all areas of the hospital and clinics, but read more about cancer and blood disorders research below.

  • “Race Matters: Perceptions of Race and Racism in a Sickle Cell Center.” Pediatric Blood and Cancer. March 2013.
  • “Scaring Athletes with Sickle Cell Trait.” American Journal of Cardiology. January 2013.
  • “Dismantling Racism to Improve Health Equity.” In Health Disparities: Epidemiology, Racial/Ethnic and Socioeconomic Risk Factors and Strategies for Elimination. Nova Publishers, New York, 2013, in press.
  • “The Pediatric-Modified Total Neuropathy Score: A Reliable and Valid Measure of Chemotherapy-Induced Peripheral Neuropathy in Children with Non-CNS Cancers.” Journal of Supportive Care in Cancer. March 2013.
  • “Comparison of the ped-mTNS with the Common Toxicity Criteria for the Measurement of Chemotherapy-Induced Peripheral Neuropathy in Children.” Submitted to Pediatric Blood and Cancer April 2013.
  • “Successful Management of Factor IX Inhibitor-Associated Nephrotic Syndrome in a Hemophilia B Patient.” Pediatric Nephrology. May 2013.
  • “Ofatumumab for Refractory Opsoclonus-Myoclonus Syndrome Following Treatment of Neuroblastoma.” Pediatric Blood and Cancer. June 2013. [Epub ahead of print]
  • “Impact of Treatment Exposures on Cardiovascular Risk and Insulin Resistance in Childhood Cancer Survivors.” Cancer Epidemiology, Biomarkers and Prevention. In press.


At Children’s Minnesota, we know how important reliable information about conditions and illnesses is.